| Source Date | Board Meeting Date | Details |
|
04-Dec-2025
|
06-Dec-2025
|
Preferential Issue of shares & Inter alia, to consider and approve the proposals for: a. investment in Biocon Biologics Limited (?BBL?), an unlisted material subsidiary of the Company, by way of purchase or acquisition of securities from shareholders of BBL, for cash and/or consideration other than cash through issuance and allotment of fully paid-up equity shares of the Company on a preferential allotment basis through private placement to such shareholders, in accordance with Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018; and b. raising of funds by way of issuance of commercial paper through private placement and/or equity shares or any other eligible securities, through one or more permissible modes including but not limited to qualified institutions placement, rights issue, preferential issue and further public offer etc., in one or more tranchesin compliance with applicable laws and subject to requisite approvals as may be necessary, including approval of shareholders of the Company, as may be required, in this regard at an Extra-Ordinary General Meeting.
|
|
06-Oct-2025
|
11-Nov-2025
|
Quarterly Results
|
|
29-Sep-2025
|
01-Oct-2025
|
Redemption(Part) of NCD Inter alia, it is proposed to consider early redemption of unlisted, secured, rated, redeemable, Non-Convertible Debentures (NCDs) of face value of INR 1,00,000/- each, issued and allotted by the Company on private placement basis on February 21, 2023, subject to approval of the Board of Directors of the Company proposed to be sought on October 01, 2025, and receipt of necessary approvals, on such date as may be determined by the Company.
|
|
08-Jul-2025
|
07-Aug-2025
|
Quarterly Results
|
|
21-Apr-2025
|
23-Apr-2025
|
Inter alia, to consider and approve the proposal for raising of funds by way of issue of equity shares or any other eligible securities, through one or more of the permissible modes including but not limited to qualified institutions placement, rights issue, preferential issue, further public offer, etc.
|
|
02-Apr-2025
|
08-May-2025
|
Final Dividend & Audited Results
|
|
01-Apr-2025
|
04-Apr-2025
|
Inter alia, to consider and approve raising funds through issuance of Commercial Papers or through any other mode
|
|
23-Jan-2025
|
27-Jan-2025
|
Inter alia, to consider and approve:- (1) Raising of Funds through issuance of Commercial Papers (CPs) or through any other mode on private placement basis.
|
|
03-Jan-2025
|
30-Jan-2025
|
Quarterly Results
|
|
03-Oct-2024
|
30-Oct-2024
|
Quarterly Results
|
|
18-Jul-2024
|
08-Aug-2024
|
Quarterly Results
|
|
12-Apr-2024
|
16-May-2024
|
Audited Results & Final Dividend
|
|
10-Jan-2024
|
08-Feb-2024
|
Quarterly Results
|
|
09-Oct-2023
|
10-Nov-2023
|
Quarterly Results
|
|
21-Jul-2023
|
10-Aug-2023
|
Quarterly Results
|
|
24-Apr-2023
|
26-Apr-2023
|
Inter alia, to consider the issue of Secured, Redeemable, Non-Convertible Debentures on private placement basis, investment in securities to be issued by Biocon Biologics Limited and provision of guarantees/put options, amongst other matters.
|
|
20-Apr-2023
|
23-May-2023
|
Final Dividend & Audited Results & A.G.M.
|
|
06-Jan-2023
|
14-Feb-2023
|
Quarterly Results
|
|
20-Oct-2022
|
14-Nov-2022
|
Quarterly Results
|
|
01-Jul-2022
|
27-Jul-2022
|
Quarterly Results
|